One of the largest ophthalmic medical institutions in China, a leading chain enterprise of private ophthalmic hospitals. Mainly to provide patients with various ophthalmic diseases diagnosis and treatment, medical optometry and other ophthalmic medical services. Looking back on nearly 30 trading days, Aier Ophthalmology dropped by 24.43%, the highest price was 44.4 yuan, and the total turnover was 65.438+27.8 million lots.
2. Zheng Jun (300223): Leading stock. Judging from the net profit in the past three years, the average net profit in the past three years is 48.46 million yuan, and the lowest net profit in the past three years is 20 18 years13.52 million yuan, and the highest is 73.2 million yuan in 2020. The stock price fell by 24.99% in recent 30 days, and by -2 1.26% in 2022.
3. Pharmaceutical industry (300558): leading stock. Judging from the net profit in the past three years, the average net profit in the past three years was 335 million yuan, and the lowest net profit in the past three years was 654.38+668 million yuan in 20 18, and the highest was 606.4 million yuan in 2020. Innovate the industry standard of scarcity of anticancer drugs, and build the first small molecule targeted anticancer drug Kemena independently developed by China; The pipeline thickness of new drug research and development is second only to Hengrui Pharma; Clinical phase III varieties include ALK inhibitor Ashatinib and anti-angiogenesis inhibitor Vorolanib for non-small cell lung cancer and various solid tumors; For ophthalmology; Promote the clinical scheme of targeted drug Ensatinib in the treatment of ALK fusion mutation positive non-small cell lung cancer; 65438+In June 2008, the self-developed new anti-tumor drug BPI- 16350 capsule was approved for clinical trial, and the American subsidiary X82 targeted anticancer drug and monoclonal antibody Opdivo were jointly treated in the United States 1/2.